サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654288

無菌注射剤CDMOの市場規模、シェア、動向分析レポート：分子タイプ別、製品別、サービス別、治療領域別、投与経路別、最終用途別、地域別、セグメント予測、2025年～2030年

Sterile Injectables CDMO Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, Large Molecule), By Product, By Service, By Therapeutic Area, By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 180 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
無菌注射剤CDMOの市場規模、シェア、動向分析レポート：分子タイプ別、製品別、サービス別、治療領域別、投与経路別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月20日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

無菌注射剤CDMO市場動向：

世界の無菌注射剤CDMO市場規模は2024年に42億5,000万米ドルと推計され、2025年から2030年にかけてCAGR 9.61％で成長すると予測されています。

市場成長の主因は、注射薬のパイプラインと承認の増加です。製薬会社は、作用発現の速さ、正確な投与、患者の服薬アドヒアランスの向上など、数多くの利点がある注射薬の開発に積極的に注力しています。

例えば、2024年1月に発表された米国食品医薬品局（FDA）の報告書によると、医薬品評価研究センター（CDER）は2023年に55の新薬を承認しました。これらの医薬品には注射剤も含まれており、強力なパイプラインがあることを示しています。このパイプラインは、商業目的および研究目的の両方における受託製造サービスの需要増加を促進し、したがって市場全体の成長に寄与すると予想されます。

細胞治療や遺伝子治療に対する需要の増加が市場の成長を牽引しています。治療パイプラインの拡大に伴い、製造受託機関（CMO）が提供する専門的な製造能力に対する要求が高まっています。例えば、米国遺伝子・細胞治療学会（ASGCT）によると、現在3,866の治療法が開発中であり、その範囲は前臨床段階から登録前までとなっています。この中で、2,082の治療法が遺伝子治療に分類され、CAR T細胞治療のような遺伝子改変細胞治療が含まれ、遺伝子・細胞・RNA治療の53％を占めています。さらに、862の治療法は非遺伝子組換え細胞療法であり、開発中の遺伝子・細胞・RNA治療法全体の22％を占めています。このように、強力な製品パイプラインと先端治療薬に対する需要の高まりが、市場全体の需要を高めると考えられます。

市場参入企業は、無菌製造施設の拡大や共同研究・提携などの戦略的イニシアチブをとっており、予測期間を通じて市場の成長を後押しすると予想されます。例えば、2024年3月、アルカミコーポレーションはタンベックスCDMOと提携し、生物製剤の製造能力を強化しました。Alcami社は無菌充填、ラベリング、包装の専門知識を活用し、Tanvex社はハイスループット原薬開発サービスを提供します。このパートナーシップは、特殊治療薬や複雑な生物製剤の需要増加に対応し、無菌注射剤の供給を迅速化することを目的としています。

無菌注射剤の需要の高さは、製造委託先とバイオ製薬企業間の外部委託契約の成長を促進し、無菌注射剤CDMO業界の成長を後押ししています。迅速な薬効、迅速な吸収、より少ない薬物濃度に対するニーズの高まりは、無菌注射剤CDMO産業の採用に貢献しているいくつかの主要な側面です。さらに、無菌注射剤の開発と製造に積極的に関与する製薬会社は、モノクローナル抗体療法、高分子注射剤、感染症治療薬をサポートするために牽引力を増しています。ジェネリック注射剤の研究開発サイクルの時間短縮とコスト削減、希少疾患治療の進展など、いくつかの要因が市場の成長を加速させています。

がん治療薬の安定性と有効性を確保するためには、高度な製造技術が不可欠です。無菌注射剤を専門とする受託製造業者、特に複雑な製剤や生物学的製剤の取り扱い経験が豊富な製造業者は、がん治療薬特有の要件に対応できる体制を整えています。無菌注射剤は、がん治療において複雑な生物製剤や革新的な治療法を提供するために不可欠であり、無菌注射剤受託製造セクターの成長を牽引しています。アウトソーシングの拡大は、予測期間中の同分野の拡大を促進すると予想されます。製薬会社、特にがん領域に特化した製薬会社は、プロセスの合理化、コスト削減、製造委託先が提供する専門的知識の活用を目的として、製造業務のアウトソーシングに目を向けるようになっています。このシフトは、がん分野の無菌注射剤開発・製造受託市場を顕著に押し上げています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 無菌注射剤CDMO市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 補助市場の見通し
  • 市場力学
    • 市場ドライバー分析
    • 市場抑制要因分析
  • 技術の進歩
  • 価格モデル分析
  • 臨床試験ボリューム分析、2023年
    • 地域別臨床試験総数（2023年）
    • 臨床試験の総数（フェーズ別）（2023年）
    • 臨床試験の総数（研究デザイン別）（2023年）
    • 主要治療領域別臨床試験総数（2023年）
  • 滅菌注射剤CDMO市場：分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
  • COVID-19の影響分析

第4章 無菌注射剤CDMO市場：分子タイプの推定・動向分析

  • セグメントダッシュボード
  • 世界の無菌注射剤CDMO市場変動分析
  • 世界の無菌注射剤CDMO市場規模と動向分析、分子タイプ別、2018年から2030年
  • 小分子
  • 巨大分子

第5章 無菌注射剤CDMO市場：製品の推定・動向分析

  • セグメントダッシュボード
  • 世界の無菌注射剤CDMO市場変動分析
  • 世界の無菌注射剤CDMO市場規模と動向分析、製品別、2018年から2030年
  • プレフィルドシリンジ
  • バイアルとアンプル
  • 特殊注射剤
  • その他

第6章 無菌注射剤CDMO市場：サービスの推定・動向分析

  • セグメントダッシュボード
  • 世界の無菌注射剤CDMO市場変動分析
  • 世界の無菌注射剤CDMO市場規模と動向分析、サービス別、2018年から2030年
  • 処方開発
  • 分析および試験サービス
    • 方法の開発と検証
    • 安定性テスト
    • 抽出・浸出試験
    • その他
  • 製造業
    • 臨床試験製造
    • 商業製造業
    • 無菌充填・仕上げサービス
  • パッケージング
  • 保管
    • 冷蔵
    • 非冷蔵
  • その他

第7章 無菌注射剤CDMO市場：治療領域の推定・動向分析

  • セグメントダッシュボード
  • 世界の無菌注射剤CDMO市場治療領域の変動分析
  • 世界の無菌注射剤CDMO市場規模と動向分析、治療領域、2018年から2030年
  • 腫瘍学
  • 心血管疾患
  • 中枢神経系疾患
  • 感染症
  • 筋骨格系疾患
  • ホルモン疾患
  • その他

第8章 無菌注射剤CDMO市場：投与経路の推定・動向分析

  • セグメントダッシュボード
  • 世界の無菌注射剤CDMO市場投与経路の変動分析
  • 世界の無菌注射剤CDMO市場規模と動向分析、投与経路、2018年から2030年
  • 皮下（SC）
  • 静脈内（IV）
  • 筋肉内（IM）
  • その他

第9章 無菌注射剤CDMO市場：最終用途別のモダリティの推定・動向分析

  • セグメントダッシュボード
  • 世界の無菌注射剤CDMO市場最終用途の変動分析
  • 世界の無菌注射剤CDMO市場規模と動向分析、最終用途、2018年から2030年
  • 製薬会社
  • バイオ医薬品企業
  • その他

第10章 無菌注射剤CDMO市場：地域推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
    • ベトナム
    • インドネシア
    • マレーシア
    • フィリピン
    • シンガポール
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 競合情勢

  • 市場参入企業の分類
    • マーケットリーダー
    • 新興企業
  • サービスヒートマップ分析（企業同士の比較分析）
  • 企業プロファイル
    • Boehringer Ingelheim International GmbH
    • Baxter Simtra Bio Pharma Solutions
    • Vetter Pharma International GmbH
    • Recipharm AB
    • Aenova Group
    • Fresenius Kabi Contract Manufacturing（Fresenius Kabi AG）
    • Unither Pharmaceuticals
    • FAMAR Health Care Services
    • Ajinomoto Bio-Pharma
    • PCI Pharma Services
    • IDT Biologika GmbH
    • Alcami Corporation
    • Fareva Group
    • Eurofins Scientific
    • Siegfried AG
    • Torbay Pharmaceuticals
    • Pfizer CentreOne（Pfizer Inc）
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 List of Abbreviations
  • Table 4 Global Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 5 Global Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 Global Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 7 Global Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 8 Global Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 Global Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 Global Sterile Injectables CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 11 North America Sterile Injectables CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 12 North America Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 13 North America Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 14 North America Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 15 North America Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 16 North America Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 North America Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 North America Sterile Injectables CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 19 U.S. Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 20 U.S. Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 U.S. Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 22 U.S. Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 23 U.S. Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 U.S. Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Canada Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 26 Canada Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Canada Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 28 Canada Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 29 Canada Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Canada Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 31 Mexico Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 32 Mexico Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Mexico Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 34 Mexico Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 35 Mexico Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Mexico Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 Europe Sterile Injectables CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 38 Europe Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 39 Europe Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 40 Europe Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 41 Europe Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 42 Europe Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Europe Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Europe Sterile Injectables CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 45 UK Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 46 UK Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 47 UK Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 48 UK Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 49 UK Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 UK Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Germany Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 52 Germany Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 53 Germany Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 54 Germany Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 55 Germany Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 Germany Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 France Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 58 France Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 59 France Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 60 France Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 61 France Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 France Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Italy Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 64 Italy Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 65 Italy Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 66 Italy Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 67 Italy Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Italy Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Spain Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 70 Spain Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 71 Spain Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 72 Spain Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 73 Spain Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Spain Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 75 Denmark Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 76 Denmark Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 77 Denmark Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 78 Denmark Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 79 Denmark Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Denmark Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 81 Sweden Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 82 Sweden Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 83 Sweden Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 84 Sweden Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 85 Sweden Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 Sweden Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Norway Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 88 Norway Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 89 Norway Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 90 Norway Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 91 Norway Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Norway Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 93 Asia Pacific Sterile Injectables CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 94 Asia Pacific Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 95 Asia Pacific Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 96 Asia Pacific Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 97 Asia Pacific Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 98 Asia Pacific Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 99 Asia Pacific Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 100 Asia Pacific Sterile Injectables CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 101 Japan Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 102 Japan Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 103 Japan Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 104 Japan Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 105 Japan Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 Japan Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 107 China Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 108 China Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 109 China Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 110 China Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 111 China Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 112 China Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 113 India Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 114 India Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 115 India Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 116 India Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 117 India Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 118 India Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 119 South Korea Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 120 South Korea Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 121 South Korea Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 122 South Korea Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 123 South Korea Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 124 South Korea Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 125 Australia Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 126 Australia Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 127 Australia Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 128 Australia Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 129 Australia Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 130 Australia Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 131 Thailand Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 132 Thailand Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 133 Thailand Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 134 Thailand Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 135 Thailand Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 136 Thailand Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 137 Vietnam Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 138 Vietnam Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 139 Vietnam Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 140 Vietnam Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 141 Vietnam Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 142 Vietnam Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 143 Indonesia Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 144 Indonesia Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 145 Indonesia Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 146 Indonesia Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 147 Indonesia Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 148 Indonesia Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 149 Malaysia Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 150 Malaysia Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 151 Malaysia Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 152 Malaysia Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 153 Malaysia Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 154 Malaysia Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 155 Philippines Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 156 Philippines Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 157 Philippines Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 158 Philippines Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 159 Philippines Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 160 Philippines Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 161 Singapore Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 162 Singapore Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 163 Singapore Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 164 Singapore Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 165 Singapore Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 166 Singapore Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 167 Latin America Sterile Injectables CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 168 Latin America Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 169 Latin America Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 170 Latin America Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 171 Latin America Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 172 Latin America Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 173 Latin America Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 174 Latin America Sterile Injectables CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 175 Brazil Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 176 Brazil Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 177 Brazil Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 178 Brazil Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 179 Brazil Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 180 Brazil Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 181 Argentina Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 182 Argentina Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 183 Argentina Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 184 Argentina Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 185 Argentina Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 186 Argentina Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 187 Middle East & Africa Sterile Injectables CDMO Market, by Country, 2018 - 2030 (USD Million)
  • Table 188 Middle East & Africa Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 189 Middle East & Africa Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 190 Middle East & Africa Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 191 Middle East & Africa Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 192 Middle East & Africa Sterile Injectables CDMO Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 193 Middle East & Africa Sterile Injectables CDMO Market, by End Use, 2018 - 2030 (USD Million)
  • Table 194 Middle East & Africa Sterile Injectables CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 195 South Africa Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 196 South Africa Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 197 South Africa Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 198 South Africa Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 199 Saudi Arabia Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 200 Saudi Arabia Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 201 Saudi Arabia Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 202 Saudi Arabia Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 203 UAE Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 204 UAE Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 205 UAE Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 206 UAE Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 207 Kuwait Sterile Injectables CDMO Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 208 Kuwait Sterile Injectables CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 209 Kuwait Sterile Injectables CDMO Market, by Service, 2018 - 2030 (USD Million)
  • Table 210 Kuwait Sterile Injectables CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Sterile injectables CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market outlook, 2023 (USD Billion)
  • Fig. 14 Ancillary market outlook, 2023 (USD Billion)
  • Fig. 15 Sterile injectables CDMO market dynamics
  • Fig. 16 US FDA biologics approval
  • Fig. 17 Average cost by phase
  • Fig. 18 Clinical trial cost per indication (USD millions)
  • Fig. 19 Average cost of clinical trials by major countries
  • Fig. 20 Porter's five forces analysis
  • Fig. 21 Sterile injectables CDMO market: PESTEL analysis
  • Fig. 22 Sterile injectables CDMO market: Molecule type outlook and key takeaways
  • Fig. 23 Sterile injectables CDMO market: Molecule type movement analysis
  • Fig. 24 Small molecule market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Large molecule market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Sterile injectables CDMO market: Product outlook and key takeaways
  • Fig. 27 Sterile injectables CDMO market: Product movement analysis
  • Fig. 28 Prefilled syringes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Vials and ampoules market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Specialty injectables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Sterile injectables CDMO market: Service outlook and key takeaways
  • Fig. 33 Sterile injectables CDMO market: Service movement analysis
  • Fig. 34 Formulation development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Analytical and testing services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Method development and validation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Stability testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Drug substance market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Stability-indicating method validation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Accelerated stability testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Photostability testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Other stability testing methods market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Extractable & leachable testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Clinical trial manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Commercial manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Aseptic fill-finish services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Packaging market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Storage market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Cold storage market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Non-cold storage market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Sterile injectables CDMO market: Therapeutic area outlook and key takeaways
  • Fig. 55 Sterile injectables CDMO market: Therapeutic area movement analysis
  • Fig. 56 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Central nervous system diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Infectious disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Musculoskeletal diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Hormonal diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Sterile injectables CDMO market: Route of administration outlook and key takeaways
  • Fig. 64 Sterile injectables CDMO market: Route of administration movement analysis
  • Fig. 65 Subcutaneous market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Intravenous (IV) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Intramuscular (IM) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Sterile injectables CDMO market: End-use outlook and key takeaways
  • Fig. 70 Sterile injectables CDMO market: End-use movement analysis
  • Fig. 71 Pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Biopharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Regional market: Key takeaways
  • Fig. 75 Regional marketplace: Key takeaways 1
  • Fig. 76 Regional marketplace: Key takeaways 2
  • Fig. 77 North America sterile injectables CDMO market estimates and forecast, 2018 - 2030 (, 2018 - 2030 (, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 US sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Canada sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Mexico sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Europe sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 UK sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Germany sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 France sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Italy sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Spain sterile injectables CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Denmark sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Sweden sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Norway sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 101 Asia Pacific sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 Japan sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 China sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 India sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 South Korea sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Australia sterile injectables CDMO market estimates and forecast, 2018 - 2030, (USD Million)
  • Fig. 111 Thailand sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 112 Key country dynamics
  • Fig. 113 Vietnam sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 114 Key country dynamics
  • Fig. 115 Indonesia sterile injectables CDMO market estimates and forecast, 2018 - 2030, (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Malaysia sterile injectables CDMO market estimates and forecast, 2018 - 2030, (USD Million)
  • Fig. 118 Key country dynamics
  • Fig. 119 Philippines sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 120 Key country dynamics
  • Fig. 121 Singapore sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 122 Latin America sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 123 Key country dynamics
  • Fig. 124 Brazil sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 125 Key country dynamics
  • Fig. 126 Argentina sterile injectable CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 127 Key country dynamics
  • Fig. 128 Colombia sterile injectable CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 129 Key country dynamics
  • Fig. 130 Chile sterile injectable CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 131 MEA sterile injectable CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 132 Key country dynamics
  • Fig. 133 South Africa sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 134 Key country dynamics
  • Fig. 135 Saudi Arabia sterile injectable CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 136 Key country dynamics
  • Fig. 137 UAE sterile injectable CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 138 Key country dynamics
  • Fig. 139 Kuwait sterile injectables CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 140 Key company categorization
  • Fig. 141 Service heat map analysis
  • Fig. 142 Competitive assessment analysis
  • Fig. 143 Strategic framework
目次
Product Code: GVR-4-68040-363-5

Sterile Injectables CDMO Market Trends:

The global sterile injectables CDMO market size was estimated at USD 4.25 billion in 2024 and is projected to grow at a CAGR of 9.61% from 2025 to 2030. The market growth is primarily driven by increasing pipeline and approvals of injectable drugs. Pharmaceutical companies are proactively focusing on developing injectable medications due to their numerous benefits, such as quicker onset of action, precise dosing, and enhanced patient adherence.

For instance, as per the U.S. Food and Drug Administration (FDA) report published in January 2024, the Center for Drug Evaluation and Research (CDER) approved 55 novel drugs in 2023. These medications included injectables, indicating a robust pipeline that is anticipated to drive an increase in the demand for contract manufacturing services for both commercial and research purposes, hence contributing to overall market growth.

The increasing demand for cellular and genetic therapies is driving the market's growth. With the expansion of therapy pipelines, there is a rising requirement for specialized manufacturing capabilities provided by contract manufacturing organizations (CMOs). For instance, according to the American Society of Gene & Cell Therapy (ASGCT), 3,866 therapies are currently in development, spanning from preclinical stages through preregistration. Within this landscape, 2,082 therapies are categorized as gene therapies, which include genetically modified cell therapies like CAR T-cell therapies, constituting 53% of gene, cell, and RNA therapies. In addition, 862 therapies are nongenetically modified cell therapies, making up 22% of the overall gene, cell, and RNA therapies in development. Thus, a strong product pipeline and growing demand for advanced therapeutics are likely to enhance overall market demand.

Strategic initiatives undertaken by market participants, such as expanding sterile manufacturing facilities and engaging in collaborations and partnerships, are anticipated to bolster market growth throughout the projected period. For instance, in March 2024, Alcami Corporation company partnered with Tanvex CDMO, enhancing its capabilities in biologics manufacturing. Alcami would leverage its expertise in sterile filling, labeling, and packaging, while Tanvex would contribute its high-throughput bulk drug substance development services. The partnership aimed to expedite the delivery of sterile injectables, addressing the increasing demand for specialty therapeutics and complex biologics.

The high demand for sterile injectables propels growth in outsourced agreements amongst contract manufacturers and biopharmaceutical companies, thereby boosting the growth of the sterile injectable CDMO industry. The growing need for faster drug action, rapid absorption, and less drug concentration are a few major aspects contributing to the adoption of sterile injectables CDMO industry. Further, pharmaceutical firms actively involved in sterile injectable development and manufacturing are gaining traction to support monoclonal antibody therapies, large-molecule injectable drugs, and infectious disease-treating drugs. Several factors, including reduced time and cost-affordable research and development cycles of generic injectables and the growing advancements in rare disease treatments, are accelerating the market growth.

Advanced manufacturing techniques are crucial for ensuring the stability and efficacy of cancer therapies. Contract manufacturers specializing in sterile injectables, particularly those experienced in handling complex formulations and biologics, are well-equipped to address the specific requirements of oncology drugs. Sterile injectables are essential for delivering complex biologics and innovative treatment methods in cancer treatment, driving the growth of the sterile injectable contract manufacturing sector. The growth in outsourcing practices is expected to drive the expansion of the segment over the forecast period. Pharmaceutical companies, particularly those specializing in oncology, are increasingly turning to outsourcing manufacturing operations to streamline processes, cut costs, and capitalize on the specialized expertise offered by contract manufacturers. This shift has notably boosted the cancer sector's sterile injectable contract development and manufacturing market.

Global Sterile Injectables CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global sterile injectables CDMO market report based on molecule type, product, service, therapeutic area, route of administration, end-use, and region.

  • Molecule Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Small Molecule
  • Large Molecule
  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Pre-filled Syringes
  • Vials and Ampoules
  • Specialty Injectables
  • Others
  • Service Outlook (Revenue, USD Million, 2018 - 2030)
  • Formulation Development
  • Analytical and Testing Services
    • Method Development and Validation
    • Stability Testing
    • Drug Substance
    • Stability Indicating Method Validation
    • Accelerated Stability Testing
    • Photostability Testing
    • Other Stability Testing Methods
    • Extractable & Leachable Testing
    • Others
  • Manufacturing
    • Clinical Trial Manufacturing
    • Commercial Manufacturing
    • Aseptic Fill-Finish Services
  • Packaging
  • Storage
    • Cold
    • Non-cold
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Cardiovascular Diseases
  • Central Nervous System Diseases
  • Infectious Disorders
  • Musculoskeletal Diseases
  • Hormonal Diseases
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Subcutaneous (SC)
  • Intravenous (IV)
  • Intramuscular (IM)
  • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
    • Vietnam
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
    • 1.2.1. Molecule Type
    • 1.2.2. Product
    • 1.2.3. Service
    • 1.2.4. Therapeutic Area
    • 1.2.5. Route of Administration
    • 1.2.6. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
    • 1.6.1. Region Wise Market: Base Estimates
    • 1.6.2. Global Market: CAGR Calculation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis (Model 1)
    • 1.7.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.7.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.7.4. Bottom-Up Approach (Model 4)
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Sterile Injectables CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
      • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
      • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
      • 3.2.1.4. Increasing Demand for One-stop-shop CDMOs
      • 3.2.1.5. Increasing Outsourcing Services by Pharmaceutical Companies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
      • 3.2.2.3. Compliance issues while outsourcing
      • 3.2.2.4. Contractual Obligation
  • 3.3. Technological Advancements
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2023
    • 3.5.1. Total Number of Clinical Trials, by Region (2023)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.6. Sterile Injectables CDMO Market: Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Sterile Injectables CDMO Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 4.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Sterile Injectables CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 5.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 5.4. Pre-filled Syringes
    • 5.4.1. Pre-filled Syringes Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Vials and Ampoules
    • 5.5.1. Vials and Ampoules Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.6. Specialty Injectables
    • 5.6.1. Specialty Injectables Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Sterile Injectables CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 6.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 6.4. Formulation Development
    • 6.4.1. Formulation Development Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Analytical and Testing Services
    • 6.5.1. Analytical and Testing Services Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.5.2. Method Development and Validation
      • 6.5.2.1. Method Development and Validation Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.5.3. Stability Testing
      • 6.5.3.1. Stability Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 6.5.3.2. Drug Substance
        • 6.5.3.2.1. Drug Substance Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 6.5.3.3. Stability Indicating Method Validation
        • 6.5.3.3.1. Stability Indicating Method Validation Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 6.5.3.4. Accelerated Stability Testing
        • 6.5.3.4.1. Accelerated Stability Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 6.5.3.5. Photostability Testing
        • 6.5.3.5.1. Photostability Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
      • 6.5.3.6. Other Stability Testing Methods
        • 6.5.3.6.1. Other Stability Testing Methods Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.5.4. Extractable & Leachable Testing
      • 6.5.4.1. Extractable & Leachable Testing Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.5.5. Others
      • 6.5.5.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Manufacturing
    • 6.6.1. Manufacturing Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.6.2. Clinical Trial Manufacturing
      • 6.6.2.1. Clinical Trial Manufacturing Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.6.3. Commercial Manufacturing
      • 6.6.3.1. Commercial Manufacturing Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.6.4. Aseptic Fill-Finish Services
      • 6.6.4.1. Aseptic Fill-Finish Services Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.7. Packaging
    • 6.7.1. Packaging Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.8. Storage
    • 6.8.1. Storage Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.8.2. Cold
      • 6.8.2.1. Cold Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 6.8.3. Non-cold
      • 6.8.3.1. Non-cold Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Sterile Injectables CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Sterile Injectables CDMO Market Therapeutic Area Movement Analysis
  • 7.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Therapeutic Area, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Cardiovascular Diseases
    • 7.5.1. Cardiovascular Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Central Nervous System Diseases
    • 7.6.1. Central Nervous System Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Infectious Disorders
    • 7.7.1. Infectious Disorders Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.8. Musculoskeletal Diseases
    • 7.8.1. Musculoskeletal Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.9. Hormonal Diseases
    • 7.9.1. Hormonal Diseases Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Sterile Injectables CDMO Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Sterile Injectables CDMO Market Route of Administration Movement Analysis
  • 8.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Route of Administration, 2018 to 2030 (USD Million)
  • 8.4. Subcutaneous (SC)
    • 8.4.1. Subcutaneous (SC) Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5. Intravenous (IV)
    • 8.5.1. Intravenous (IV) Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6. Intramuscular (IM)
    • 8.6.1. Intramuscular (IM) Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Sterile Injectables CDMO Market: Modality by End Use Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Sterile Injectables CDMO Market End Use Movement Analysis
  • 9.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, End Use, 2018 to 2030 (USD Million)
  • 9.4. Pharmaceutical Companies
    • 9.4.1. Pharmaceutical Companies Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 9.5. Biopharmaceutical Companies
    • 9.5.1. Biopharmaceutical Companies Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 10. Sterile Injectables CDMO Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2024 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. North America
    • 10.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.3.2. U.S.
      • 10.3.2.1. Key Country Dynamics
      • 10.3.2.2. Competitive Scenario
      • 10.3.2.3. Regulatory Framework
      • 10.3.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.3.3. Canada
      • 10.3.3.1. Key Country Dynamics
      • 10.3.3.2. Competitive Scenario
      • 10.3.3.3. Regulatory Framework
      • 10.3.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.3.4. Mexico
      • 10.3.4.1. Key Country Dynamics
      • 10.3.4.2. Competitive Scenario
      • 10.3.4.3. Regulatory Framework
      • 10.3.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.4. Europe
    • 10.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.2. UK
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.3. Germany
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.4. France
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.5. Italy
      • 10.4.5.1. Key Country Dynamics
      • 10.4.5.2. Competitive Scenario
      • 10.4.5.3. Regulatory Framework
      • 10.4.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.6. Spain
      • 10.4.6.1. Key Country Dynamics
      • 10.4.6.2. Competitive Scenario
      • 10.4.6.3. Regulatory Framework
      • 10.4.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.7. Denmark
      • 10.4.7.1. Key Country Dynamics
      • 10.4.7.2. Competitive Scenario
      • 10.4.7.3. Regulatory Framework
      • 10.4.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.8. Sweden
      • 10.4.8.1. Key Country Dynamics
      • 10.4.8.2. Competitive Scenario
      • 10.4.8.3. Regulatory Framework
      • 10.4.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.9. Norway
      • 10.4.9.1. Key Country Dynamics
      • 10.4.9.2. Competitive Scenario
      • 10.4.9.3. Regulatory Framework
      • 10.4.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.5. Asia Pacific
    • 10.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.2. Japan
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Competitive scenario
      • 10.5.2.3. Regulatory framework
      • 10.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.3. China
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Competitive scenario
      • 10.5.3.3. Regulatory framework
      • 10.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.4. India
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Competitive scenario
      • 10.5.4.3. Regulatory framework
      • 10.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.5. South Korea
      • 10.5.5.1. Key country dynamics
      • 10.5.5.2. Competitive scenario
      • 10.5.5.3. Regulatory framework
      • 10.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.6. Australia
      • 10.5.6.1. Key country dynamics
      • 10.5.6.2. Competitive scenario
      • 10.5.6.3. Regulatory framework
      • 10.5.6.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.7. Thailand
      • 10.5.7.1. Key country dynamics
      • 10.5.7.2. Competitive scenario
      • 10.5.7.3. Regulatory framework
      • 10.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.8. Vietnam
      • 10.5.8.1. Key country dynamics
      • 10.5.8.2. Competitive scenario
      • 10.5.8.3. Regulatory framework
      • 10.5.8.4. Vietnam market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.9. Indonesia
      • 10.5.9.1. Key country dynamics
      • 10.5.9.2. Competitive scenario
      • 10.5.9.3. Regulatory framework
      • 10.5.9.4. Indonesia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.10. Malaysia
      • 10.5.10.1. Key country dynamics
      • 10.5.10.2. Competitive scenario
      • 10.5.10.3. Regulatory framework
      • 10.5.10.4. Malaysia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.11. Philippines
      • 10.5.11.1. Key country dynamics
      • 10.5.11.2. Competitive scenario
      • 10.5.11.3. Regulatory framework
      • 10.5.11.4. Philippines market estimates and forecasts, 2018 to 2030 (USD Million)
    • 10.5.12. Singapore
      • 10.5.12.1. Key country dynamics
      • 10.5.12.2. Competitive scenario
      • 10.5.12.3. Regulatory framework
      • 10.5.12.4. Singapore market estimates and forecasts, 2018 to 2030 (USD Million)
  • 10.6. Latin America
    • 10.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.2. Brazil
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Framework
      • 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.3. Argentina
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Framework
      • 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.7. MEA
    • 10.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.2. South Africa
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Framework
      • 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.3. Saudi Arabia
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Framework
      • 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.4. UAE
      • 10.7.4.1. Key Country Dynamics
      • 10.7.4.2. Competitive Scenario
      • 10.7.4.3. Regulatory Framework
      • 10.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.5. Kuwait
      • 10.7.5.1. Key Country Dynamics
      • 10.7.5.2. Competitive Scenario
      • 10.7.5.3. Regulatory Framework
      • 10.7.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Service Heat Map Analysis (a comparative analysis of the players together)
  • 11.3. Company Profiles
    • 11.3.1. Boehringer Ingelheim International GmbH
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Baxter Simtra BioPharma Solutions
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Vetter Pharma International GmbH
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Recipharm AB
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Aenova Group
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Fresenius Kabi Contract Manufacturing (Fresenius Kabi AG)
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Unither Pharmaceuticals
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. FAMAR Health Care Services
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Ajinomoto Bio-Pharma
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. PCI Pharma Services
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IDT Biologika GmbH
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Alcami Corporation
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. Fareva Group
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. Eurofins Scientific
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Siegfried AG
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. Torbay Pharmaceuticals
      • 11.3.16.1. Company Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Pfizer CentreOne (Pfizer Inc)
      • 11.3.17.1. Company Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives